CONTINUOUS VERSUS INTERMITTENT SULFONYLUREA THERAPY IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS

被引：9

作者：

GRUNBERGER, G

机构：

[1] Diabetes Section, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan

[2] Wayne State University Health Center, Detroit, Michigan, 48201

来源：

DRUG SAFETY | 1993年 / 9卷 / 04期

关键词：

D O I：

10.2165/00002018-199309040-00002

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Although it is 50 years since the discovery of the hypoglycaemic effects of sulphonylureas, the molecular basis of their effects are still not fully understood. It has been suggested that long term sulphonylurea therapy may desensitise the pancreatic beta-cells to further drug effects, and that intermittent sulphonylurea therapy may be the best approach to maintain their effectiveness. A randomised, double-blind study has been carried out to attempt to answer the question of whether intermittent sulphonylurea therapy is more effective then continuous administration. Responders to oral glibenclamide (glyburide) went on to receive continuous or intermittent treatment (glibenclamide for 2 weeks then placebo for 2 weeks) for 16 weeks. Glycaemic control was maintained in the continuous treatment group. However, glucose levels deteriorated in the intermittent treatment group, suggesting that there is no merit to intermittent sulphonylurea treatment. Other strategies to investigate include administration on an alternate-day basis or a shorter period off the drug (e.g. 1 week). The underlying question of optimal glycaemic control with sulphonylureas warrants a definitive answer.

引用

页码：249 / 253

页数：5

共 16 条

[1]

Boyd A.E., Sulfonylurea receptors, ion channels and fruit flies, Diabetes, 37, pp. 847-850, (1988)

[2]

Dunbar J.C., Foa P.P., An inhibitory effect of tolbutamide and glibenclamide on the pancreatic islets of normal animals, Diabetologia, 10, pp. 27-32, (1974)

[3]

Filipponi P., Marcelli M., Nicoletti I., Pacifici R., Santeusanio F., Et al., Suppressive effect of long-term sulfonylurea treatment on A, B, and D cells of normal rat pancreas, Endocrinology, 113, pp. 1972-1979, (1983)

[4]

Gillis K.D., Gee W.M., Hammoud A., McDaniel M.L., Falke L.C., Et al., Effects of sulfonamides on a metabolite-regulated ATP-sensitive K<sup>+</sup> channel in rat pancreatic B-cells, American Journal of Physiology, 257, (1989)

[5]

Grunberger G., Maintenance of sulfonylurea responsiveness in NIDDM: randomized double-blind study of intermittent glyburide therapy, Diabetes Care, 15, pp. 696-699, (1992)

[6]

Henquin J-C, The fiftieth anniversary of hypoglycaemic sulphonamides, How did the mother compound work? Diabetologia, 35, pp. 907-912, (1992)

[7]

Henquin J.C., Meissner H.P., Opposite effects of tolbutamide and diazoxide on 86 RB fluxes and membrane potential in pancreatic B-cells, Biochemical Pharmacology, 31, pp. 1407-1415, (1982)

[8]

Lebovitz H.E., Glipizide: a second generation sulfonylurea hypoglycemic agent: pharmacology, pharmacokinetics and clinical use, Pharmacotherapy, 5, pp. 63-77, (1985)

[9]

Karam J.H., Sanz E., Salomon E., Nolte, Selective unresponsivenesss of pancreas B-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM, Diabetes, 35, pp. 1314-1320, (1986)

[10]

Melander A., Bitzen P-O, Faber O., Groop L., Sulphonylurea antidiabetic drugs: an update of their clinical pharmacology and rational therapeutic use, Drugs, 37, pp. 58-72, (1989)

← 1 2 →